Additional Relevant Details On October 29, 2016, Infinity and Verastem, entered into a license agreement, which Infinity and Verastem amended and restated on November 1, 2016, effective as of October 29, 2016. The amended and restated license agreement is referred to as the Verastem Agreement. Under the Verastem Agreement, INFI granted to VSTM an exclusive worldwide license for the research, development, commercialization, and manufacture of duvelisib and products containing duvelisib.